SNCA Key Statistics, Chart & Performance
The current stock price of SNCA is 1.66 null. In the past month the price increased by 11.41%. In the past year, price increased by 140.58%.
SNCA Latest News, Press Relases and Analysis
About SNCA
Company Profile
Seneca Biopharma Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel treatments for diseases of unmet medical need. Seneca Biopharma Inc., formerly known as Neuralstem Inc, is based in GERMANTOWN, Md.
Company Info
Seneca Biopharm Inc
20271 Goldenrod Lane
Germantown MD 20876
CEO: Kenneth Carter
Phone: 301-366-4841
Seneca Biopharm Inc / SNCA FAQ
What does Seneca Biopharm Inc do?
Seneca Biopharma Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel treatments for diseases of unmet medical need. Seneca Biopharma Inc., formerly known as Neuralstem Inc, is based in GERMANTOWN, Md.
What is the stock price of Seneca Biopharm Inc today?
The current stock price of SNCA is 1.66 null. The price decreased by -1.19% in the last trading session.
Does Seneca Biopharm Inc pay dividends?
SNCA does not pay a dividend.
What is the ChartMill technical and fundamental rating of SNCA stock?
SNCA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is Seneca Biopharm Inc worth?
Seneca Biopharm Inc (SNCA) has a market capitalization of 28.71M null. This makes SNCA a Nano Cap stock.
Can you provide the ownership details for SNCA stock?
You can find the ownership structure of Seneca Biopharm Inc (SNCA) on the Ownership tab.
SNCA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SNCA. When comparing the yearly performance of all stocks, SNCA is one of the better performing stocks in the market, outperforming 86.73% of all stocks.
SNCA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNCA. Both the profitability and financial health of SNCA have multiple concerns.
SNCA Financial Highlights
Over the last trailing twelve months SNCA reported a non-GAAP Earnings per Share(EPS) of -1.17. The EPS increased by 69.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -120494.81% | ||
| ROA | -124.66% | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |